Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 11:58 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Recurrent Disease Clear all
Withdrawn Phase 3 Interventional

First Line Comparative Study of EN3348 (MCC) vs BCG in NMIBC

NCT01284205
View directory record Official record
Conditions
Bladder Cancer
Interventions
Mycobacterial Cell-Wall DNA Complex, Bacillus Calmette-Guerin
Biological
Lead sponsor
Bioniche Life Sciences Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
14
States / cities
Laguna Hills, California • Los Angeles, California • San Diego, California + 11 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2014 · Synced Jul 22, 2026, 11:58 AM EDT
Completed Phase 3 Interventional

Hepatic Arterial Infusion With Melphalan Compared With Standard Therapy in Treating Patients With Unresectable Liver Metastases Due to Melanoma

NCT00324727
View directory record Official record
Conditions
Intraocular Melanoma, Melanoma (Skin), Metastatic Cancer
Interventions
melphalan, regional chemotherapy, systemic chemotherapy, hepatic artery embolization
Drug · Procedure
Lead sponsor
Delcath Systems Inc.
Industry
Eligibility
18 Years to 120 Years
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
12
States / cities
Santa Monica, California • Englewood, Colorado • Tampa, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 20, 2021 · Synced Jul 22, 2026, 11:58 AM EDT
Completed Not applicable Interventional Results available

Patent Foramen Ovale Closure or Medical Therapy After Stroke - RESPECT Trial

NCT00465270
View directory record Official record
Conditions
Cryptogenic Stroke
Interventions
AMPLATZER PFO Occluder, Standard of Care - Medical Management
Device · Other
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years to 60 Years
Enrollment
980 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2016
U.S. locations
61
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Los Angeles, California + 52 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2019 · Synced Jul 22, 2026, 11:58 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Pembrolizumab in Treating Patients With Stage IV Metastatic or Recurrent Inflammatory Breast Cancer or Triple-Negative Breast Cancer Who Have Achieved Clinical Response or Stable Disease to Prior Chemotherapy

NCT02411656
View directory record Official record
Conditions
Edema, Erythema, Estrogen Receptor Negative, HER2/Neu Negative, Peau d'Orange, Progesterone Receptor Negative, Recurrent Inflammatory Breast Carcinoma, Stage IV Inflammatory Breast Carcinoma, Triple-Negative Breast Carcinoma
Interventions
Laboratory Biomarker Analysis, Pembrolizumab
Other · Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Jul 22, 2026, 11:58 AM EDT
Terminated Phase 1 Interventional

To Evaluate Safety and Pharmacokinetics of Belinostat in Patients Who Have Mild, Moderate and Severe Renal Impairment.

NCT02679131
View directory record Official record
Conditions
Relapsed/Refractory Solid Tumors/Hematological Malignancies
Interventions
Belinostat
Drug
Lead sponsor
Acrotech Biopharma Inc.
Industry
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
2
States / cities
Whittier, California • Canton, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 19, 2019 · Synced Jul 22, 2026, 11:58 AM EDT
Completed Phase 2 Interventional Results available

Avatar-Directed Chemotherapy in Treating Patients With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

NCT02312245
View directory record Official record
Conditions
Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
Interventions
Bevacizumab, Gemcitabine Hydrochloride, Paclitaxel, Pegylated Liposomal Doxorubicin Hydrochloride, Topotecan Hydrochloride
Biological · Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older · Female only
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
3
States / cities
Phoenix, Arizona • Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 4, 2024 · Synced Jul 22, 2026, 11:58 AM EDT
Completed Phase 2 Interventional

Vaccine Therapy and Monoclonal Antibody Therapy in Treating Patients With Stage IV Melanoma

NCT00032045
View directory record Official record
Conditions
Intraocular Melanoma, Melanoma (Skin)
Interventions
gp100 antigen, incomplete Freund's adjuvant, ipilimumab
Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
16 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2006
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 19, 2013 · Synced Jul 22, 2026, 11:58 AM EDT
Not listed Phase 2 Interventional

Interleukin-2 in Treating Patients With Metastatic Melanoma

NCT00002845
View directory record Official record
Conditions
Melanoma (Skin)
Interventions
aldesleukin
Biological
Lead sponsor
Blumenthal Cancer Center at Carolinas Medical Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1995
U.S. locations
1
States / cities
Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 18, 2013 · Synced Jul 22, 2026, 11:58 AM EDT
Recruiting Phase 1 Interventional

Venetoclax to Augment Epigenetic Modification and Chemotherapy

NCT05317403
View directory record Official record
Conditions
Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory
Interventions
Venetoclax, Azacitadine, Vorinostat, Cytarabine, Fludarabine, Filgrastim
Drug
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
1 Year to 25 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jan 11, 2026 · Synced Jul 22, 2026, 11:58 AM EDT
Completed Phase 2 Interventional Results available

Evaluation of TRC105 in the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma

NCT01381861
View directory record Official record
Conditions
Recurrent Ovarian Cancer, Fallopian Tube Carcinoma, Primary Peritoneal Carcinoma
Interventions
Carotuximab (TRC105)
Biological
Lead sponsor
Tracon Pharmaceuticals Inc.
Industry
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
7
States / cities
Birmingham, Alabama • La Jolla, California • Los Angeles, California + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 4, 2019 · Synced Jul 22, 2026, 11:58 AM EDT
Completed Phase 1 Interventional

Vaccine Therapy and Cyclophosphamide in Treating Patients With Stage II-III Breast or Stage II-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

NCT01606241
View directory record Official record
Conditions
Recurrent Breast Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma, Stage IIA Breast Cancer, Stage IIA Fallopian Tube Cancer, Stage IIA Ovarian Cancer, Stage IIB Breast Cancer, Stage IIB Fallopian Tube Cancer, Stage IIB Ovarian Cancer, Stage IIC Fallopian Tube Cancer, Stage IIC Ovarian Cancer, Stage IIIA Breast Cancer, Stage IIIA Fallopian Tube Cancer, Stage IIIA Ovarian Cancer, Stage IIIA Primary Peritoneal Cancer, Stage IIIB Breast Cancer, Stage IIIB Fallopian Tube Cancer, Stage IIIB Ovarian Cancer, Stage IIIB Primary Peritoneal Cancer, Stage IIIC Breast Cancer, Stage IIIC Fallopian Tube Cancer, Stage IIIC Ovarian Cancer, Stage IIIC Primary Peritoneal Cancer, Stage IV Fallopian Tube Cancer, Stage IV Ovarian Cancer, Stage IV Primary Peritoneal Cancer
Interventions
Cyclophosphamide, Laboratory Biomarker Analysis, Multi-epitope Folate Receptor Alpha Peptide Vaccine
Drug · Other · Biological
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older · Female only
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 20, 2024 · Synced Jul 22, 2026, 11:58 AM EDT
Completed Phase 1Phase 2 Interventional

Vaccine Therapy in Treating Patients With Metastatic Melanoma Who Are Undergoing Surgery for Lymph Node and Tumor Removal

NCT00003229
View directory record Official record
Conditions
Melanoma (Skin)
Interventions
aldesleukin, gp100 antigen, tyrosinase peptide
Biological
Lead sponsor
Duke University
Other
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2005
U.S. locations
2
States / cities
Durham, North Carolina • Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 24, 2013 · Synced Jul 22, 2026, 11:58 AM EDT
Completed Phase 2 Interventional

Dactinomycin in Treating Patients With Persistent or Recurrent Gestational Trophoblastic Neoplasia

NCT00003688
View directory record Official record
Conditions
Gestational Trophoblastic Tumor
Interventions
dactinomycin
Biological
Lead sponsor
Gynecologic Oncology Group
Network
Eligibility
12 Years to 50 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
28
States / cities
Birmingham, Alabama • Los Gatos, California • Orange, California + 24 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2013 · Synced Jul 22, 2026, 11:58 AM EDT
Active, not recruiting No phase listed Observational

Impact of a Health Technology Intervention on Patient Activation in Multiple Myeloma

NCT05673083
View directory record Official record
Conditions
Multiple Myeloma in Relapse, Multiple Myeloma, Multiple Myeloma, Refractory, Multiple Myeloma With Failed Remission
Interventions
Not listed
Lead sponsor
All4Cure
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
7
States / cities
Fayetteville, Arkansas • Jacksonville, Florida • Des Moines, Iowa + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2025 · Synced Jul 22, 2026, 11:58 AM EDT
Completed Phase 2 Interventional Results available

A Study of Carboplatin and DOXIL Plus Bevacizumab in Patients With Platinum Sensitive Recurrent Ovarian, Fallopian Tube and Primary Peritoneal Cancers

NCT00698451
View directory record Official record
Conditions
Ovarian Neoplasms, Fallopian Tube Neoplasms, Peritoneal Neoplasms
Interventions
doxorubicin HCL liposome; bevacizumab; carboplatin
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
18 Years and older · Female only
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Horsham, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 5, 2013 · Synced Jul 22, 2026, 11:58 AM EDT
Completed Not applicable Interventional

PET Scans in Diagnosing Primary or Recurrent Cervical Cancer in Patients Who Are Undergoing Surgery

NCT00003429
View directory record Official record
Conditions
Cervical Cancer
Interventions
biopsy, computed tomography, positron emission tomography, fludeoxyglucose F 18
Procedure · Radiation
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years to 120 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2002
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 17, 2015 · Synced Jul 22, 2026, 11:58 AM EDT
Completed Phase 3 Interventional

Efficacy, Safety and Tolerability of Agomelatine in the Prevention of Relapse of Major Depressive Disorder

NCT00467402
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
agomelatine, placebo
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years to 70 Years
Enrollment
644 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
78
States / cities
Birmingham, Alabama • Peoria, Arizona • Tucson, Arizona + 64 more
Source: ClinicalTrials.gov public record
Updated Dec 22, 2020 · Synced Jul 22, 2026, 11:58 AM EDT
Completed Phase 2 Interventional

Monoclonal Antibody Plus Chemotherapy in Treating Patients With Advanced Colorectal Cancer That Overexpresses HER2

NCT00003995
View directory record Official record
Conditions
Colorectal Cancer
Interventions
trastuzumab, irinotecan hydrochloride
Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
5
States / cities
The Bronx, New York • Pittsburgh, Pennsylvania • Providence, Rhode Island + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 7, 2013 · Synced Jul 22, 2026, 11:58 AM EDT
Completed No phase listed Observational

Plegridy Observational Program

NCT02230969
View directory record Official record
Conditions
Relapsing Forms of Multiple Sclerosis
Interventions
peginterferon beta-1a
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years and older
Enrollment
1,208 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2022
U.S. locations
50
States / cities
Homewood, Alabama • Gilbert, Arizona • Scottsdale, Arizona + 44 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2022 · Synced Jul 22, 2026, 11:58 AM EDT
Terminated Phase 4 Interventional

Post-approval Study of NovoTTF-100A in Recurrent GBM Patients

NCT01756729
View directory record Official record
Conditions
Recurrent Glioblastoma Multiforme
Interventions
NovoTTF-100A
Device
Lead sponsor
NovoCure Ltd.
Industry
Eligibility
22 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
12
States / cities
Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 9 more
Source: ClinicalTrials.gov public record
Updated Mar 1, 2016 · Synced Jul 22, 2026, 11:58 AM EDT
Completed Phase 1 Interventional

Irinotecan and Alisertib in Treating Patients With Advanced Solid Tumors or Colorectal Cancer

NCT01923337
View directory record Official record
Conditions
Mucinous Adenocarcinoma of the Colon, Mucinous Adenocarcinoma of the Rectum, Recurrent Colon Cancer, Recurrent Rectal Cancer, Signet Ring Adenocarcinoma of the Colon, Signet Ring Adenocarcinoma of the Rectum, Stage IIIA Colon Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
irinotecan hydrochloride, alisertib
Drug
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Jan 3, 2019 · Synced Jul 22, 2026, 11:58 AM EDT
Not listed Phase 3 Interventional

Radiolabeled Monoclonal Antibody in the Detection and Staging of Patients With Non-Hodgkin's Lymphoma

NCT00003337
View directory record Official record
Conditions
Lymphoma
Interventions
immunoscintigraphy, technetium Tc 99m epratuzumab
Procedure · Radiation
Lead sponsor
Gilead Sciences
Industry
Eligibility
16 Years to 120 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1997
U.S. locations
4
States / cities
Los Angeles, California • Clearwater, Florida • Baltimore, Maryland + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 15, 2021 · Synced Jul 22, 2026, 11:58 AM EDT
Terminated Phase 2Phase 3 Interventional

Whey Protein Concentrate 40% Made of Milk of Immunized Cows to Aid in the Prevention of Relapse of Clostridium Difficile-Diarrhea

NCT00177775
View directory record Official record
Conditions
Positive C-Diff Culture
Interventions
MucoMilk product
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 16, 2008 · Synced Jul 22, 2026, 11:58 AM EDT
Not listed Phase 2 Interventional

Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma

NCT00085397
View directory record Official record
Conditions
Melanoma (Skin)
Interventions
autologous dendritic cell-tumor fusion vaccine, gp100 antigen, therapeutic autologous dendritic cells
Biological
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
Not listed
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
3
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 8, 2009 · Synced Jul 22, 2026, 11:58 AM EDT